Ocugen Reports Q3 2026 Financial Results and Clinical Pipeline Progress
Ocugen, Inc. (OCGN) has transitioned into a late-stage clinical organization, currently managing three active Phase III modifier gene therapy programs targeting retinitis pigmentosa, Stargardt disease, and geographic atrophy. The company reported a net loss per share of $0.01, an improvement from the previous $0.07 loss, driven by changes in derivative liability fair values. Total assets grew significantly to $108.1 million compared to $43.5 million at the end of 2025. The company maintains a strong liquidity position with $84.6 million in cash and investments, providing a financial runway into 2028. Key clinical milestones include expected top-line data for OCU400 in Q1 2027 and OCU410ST in Q2 2027. Additionally, Ocugen is expanding its global footprint through licensing agreements, including a recent deal for the MENA region that includes potential sales milestones totaling up to $255 million.
Tickers: $OCGN
Topics: biotechnology cash runway clinical trial updates earnings report